October 14, 2017 / 8:30 a.m. - 4:30 p.m.Crowne Plaza Hotel, Foster City, CA

PromotingBiosciences for

Better Human Health

The 20th Anniversary

The 20th Anniversary

ChineseBioscienceAssociation

www.cbasf.org Email: info@cbasf.org Editor-in-Chief: Fu-Ning Hsu Advertising Editor: Lena Feng Susan Liang Cover Design: Debbie Jen Banner Design: Lena Feng Content Layout Design: Fu-Ning Hsu Logo Designer: Candy Tang Published for Annual Conference, Education and Communication Copyright © 2017 CBA All rights reserved Printer: ARC Document Solutions

CONTENTS

2 President’s Message 3 Conference Chair’s Message 4 Conference Agenda 6 Invited Speakers Information 28 A Letter from the Chinese

Biopharmaceutical Association President

29 CBA Organization and History 31 Key Event - 2016 CBA 19th Annual

Conference & 2016 Ho Family Scholarship

32 Key Event - Meeting with Aidmics

Biotechnology 33 Key Event - CAN Program 34 Key Event - Meeting with Sichuan

Government Delegation 35 Key Event - CBA Annual Summer Picnic 36 Key Event - ITRI 37 Former Presidents’ Pages 40 Sponsors Information CBA appreciates the generous support from our sponsors.

President’s Message

Welcome to the 20th annual conference of the Chinese Bioscience Association (CBA). The theme of the conference is “Promoting Biosciences for Better Human Health – Celebrating CBA 20th Anniversary”.

Two decades ago, a small group of bioscience post-docs at Stanford got together looking for connections, so they formed a journal club. Amazingly, this club grew up to become a well-recognized professional organization in the Bay Area with a large membership base of over 1000 members, which is our current CBA.

CBA’s mission is to promote education, networking, and community building for life science professionals. CBA serves the community by promoting networking and knowledge-sharing among life science professionals and entrepreneurs. In the past 20 years, CBA has organized numerous scientific conferences, workshops, and other social networking events including financial workshops, education seminars and summer picnics. We've also built up strong ties across the Pacific Ocean, which has enabled our members to connect with life science communities in mainland China, Hong Kong, Taiwan, and Singapore. As one of the major non-profit organizations for life science professionals on the West Coast, CBA provides an important platform to help our members follow emerging trends and share cutting-edge knowledge in the field.

Today, in addition to celebrating our 20th anniversary, CBA has a new milestone: we will sign an agreement with another "CBA," the Chinese Biopharmaceutical Association on the east coast. This will make us to be a national society. In the future, not only will nobody get confused by two different organizations having the same abbreviation, but the unification of our two CBAs will give rise to a stronger association, where both sides prosper. Welcome our new family member from the east coast.

Finally, I would like to thank all our speakers, sponsors, members, and conference participants. Without your kind and generous support, CBA would not have been so successful. I am also truly appreciative of the tremendous support from CBA board members, advisors, and volunteers. Because of your dedication and tireless efforts, we are able to accomplish all that we have achieved!

Thank you for your continuing support. I hope you will enjoy the conference.

Best regards,

Patrick Yang, Ph.D.

2017 President

Conference Chair’s Message

On behalf of the Chinese Bioscience Association (CBA), I am pleased to welcome you to the 20th CBA Annual Conference. 2017 marks a particularly special year for our organization as we are celebrating our 20th Anniversary. From its founding in 1997, CBA has been a strong pioneer in the bilingual biosciences community. We hope to continue to support education, networking, and community-building for all biotechnology and biopharmaceutical professionals in the bay area.

The theme of this year’s conference is “Promoting Biosciences for Better Human Health --- CBA 20th

Anniversary”. The conference program was designed to touch upon all aspects of therapeutic discovery and development: from grassroots entrepreneurship and biotech investment to understanding FDA regulations and intellectual property. We wish for the diverse collection of panel discussions and distinguished speakers today to highlight the current challenges and future trends of the biosciences and their implications for human healthcare.

This year’s Annual Conference would not be possible without the generous support from our sponsors, speakers and volunteers. I send our great appreciation to CBA Annual Conference sponsors, whose generosity and passion for promoting biosciences and bettering human health made this conference possible. I would like to extend our sincere appreciation to all our speakers for their dedication and commitment in making this conference a success. I am also grateful to the vendors, who faithfully set up their booth and are enthusiastic about sharing their mission. I highly encourage you to visit them during the networking and exhibition sessions. Finally, I thank our CBA board members, advisors and volunteers for their tremendous hard work over the past few months to prepare this outstanding conference.

It is my pleasure to serve as the 2017 Conference Chair. I hope you enjoy the conference.

Best Regards,

Huifang Li, Ph.D.

Conference Agenda

8:00-8:30 am Registration, Breakfast and Exhibitions

8:30 – 8:35 am Welcome and Opening Remarks Patrick Yang, Ph.D., CBA president

8:35 – 8:40 am Conference Introduction Huifang Li, Ph.D., CBA Conference Chair

Introduction: Lin Sun-Hoffman, Ph.D., J.D.

8:40 – 9:20 am Keynote Presentation: Innovative Drug Development: Maximizing Success and Value Peony Yu, M.D. (CMO, Fibrogen Inc.)

Introduction: Mr. Caesar Ho

9:20 – 9:45 am Cepheid: from Rags to Riches Kurt Petersen, Ph.D. (Co-Founder, Cepheid Inc.)

Panel Discussion I Moderator: Mr. Caesar Ho & Mr. Ravi Mistry

9:45 – 10:25 am

Entrepreneurship Paul Hung, Ph.D. (CEO, COMBiNATi) Ben Hwang (CEO, Profusa) Dan Laser Ph.D. (CEO, Applaud Medical, Inc.) Ben Wang, Ph.D. (Co-founder, Chimera Bioengineering) Chandler Robinson, M.D. (CEO, Monopar Therapeutics)

10:25-10:40 am Networking and Exhibitions

10:40 – 11:05 am

Build Scientist Town to Save Lives with Frontier Science and Technology Mr. William Wei (VP of America Frontier Science Institute & Chief Architect of American Chinese Friendship Council)

11:05 – 11:30 am Opportunities for Biosimilar Companies under U.S. Legal System Patricia Campbell, Ph.D. (Partner, Jones Day) Bing Liang, Ph.D. (Associate Attorney, Jones Day)

11:30-11:45 am Sponsors speech

11:45-11:50 am Ho Family Scholarship Mr. Caesar Ho

11:50 – 12:00 pm CBA 20 years’ Review Patrick Yang, Ph.D.

12:00-12:30 pm Lunch and Exhibitions Introduction: Michelle Chen, Ph.D.

12:30 – 1:10 pm Keynote presentation: Avastin’s Development: The Case Study for Mega Brand Philippe Bishop, M.D. (CMO, Aratinga.bio, Inc.)

1:10 – 1:35 pm Merck San Francisco: Commitment to Science-driven

Transformational Medicines James Mu, Ph.D. (Merck Research Laboratories San Francisco)

1:35 – 2:00 pm Transformation of BeiGene via Business Development and Partnership Ji Li, Ph.D. (EVP, BeiGene)

2:00 – 2:15 pm Networking and Exhibitions Panel Discussion II

Moderator: Michelle Chen, Ph.D.

2:15 - 2:55 pm

Biotech Investment Jennifer Hu, Ph.D. (Partner, Qiming US Healthcare Fund) Alexi Ji, Ph.D./MBA (Partner, Illumina Ventures) Rajeev Dadoo, Ph.D./MBA (Partner, SR One) Vincent Xiang, Ph.D./MBA (Partner, Six Dimensions Capital)

Panel Discussion III Moderator: Patty Kiang, Ph.D.

2:55 – 3:45 pm

Biotech Supply Chain Lee-Cheng Liu, Ph.D. (President & CEO, Eirgenix) Ray Chen, Ph.D. (Sr. Director, Genscript) Amit Chaudhuri, Ph.D. (VP, Medgenome) Dan Zhang, Ph.D. (CEO, Fountain Medical Development)

Panel Discussion IV Moderator: Lin Sun-Hoffman, Ph.D., J.D.

3:45 – 4:15 pm East West Convergence - One Mind, Two Coasts Patrick Yang, Ph.D. (CBA president, west coast) Dong Shen, Ph.D. (CBA president, east coast)

4:15 – 4:25 pm Former CBA President Speech Shian-Jiun Shih, Ph.D. (CBA founding President)

4:25 – 4:30 pm Closing Remarks Huifang Li, Ph.D., CBA Conference Chair

4:30 – 7:00 pm Networking Reception

Peony Yu, M.D.

CMO

FibroGen Inc.

BIOGRAPHY

Dr. Yu, Chief Medical Officer, joined FibroGen in 2008. Dr. Yu oversees all global and regional clinical development strategies and execution of the various clinical programs, as well as providing leadership for the roxadustat program. She brings more than 25 years of pharmaceutical leadership, patient care, and drug development experience with deep expertise in all aspects of clinical and regulatory process, and with multiple prior successful NDA/MAAs for novel drugs and drug/device combos. Prior to joining FibroGen, Dr. Yu served as Vice President of Clinical Research at Anesiva Inc. Previously, Dr. Yu was Director of Clinical Development at ALZA Corporation (now Johnson & Johnson); Director of Clinical Development at Pain Therapeutics Inc.; and Assistant Director, Clinical Development, at Elan Corporation plc (now Perrigo Company plc). Earlier in her career, Dr. Yu was Head of the Department of Physical Medicine & Rehabilitation at the Palo Alto Medical Foundation. Dr. Yu received a B.S. in Chemical Engineering from University of California, Davis, and an M.D. from the UC Davis School of Medicine. She completed her residency training at Stanford University School of Medicine. Dr. Yu is a native of China

TITLE

Innovative Drug Development: Maximizing Success and Value

ABSTRACT

This session will provide an overview on the important aspects of clinical stage innovative drug development: scientific rigor, business development considerations, and global clinical regulatory strategies.

Kurt Petersen, PhD

Co-Founder,

Cepheid Inc.

BIOGRAPHY

Kurt Petersen received his BS degree cum laude in EE from UC Berkeley in 1970, and a PhD in EE from the Massachusetts Institute of Technology in 1975. Since 1982, he has co-founded six successful, high-tech companies in Silicon Valley, including Cepheid (was on NASDAQ: CPHD; acquired by Danaher in 2016 for $4B). In 2001, he was awarded the IEEE Simon Ramo Medal for his contributions to MEMS. Dr. Petersen is a member of the National Academy of Engineering and is a Life Fellow of the IEEE in recognition of his contributions to “the commercialization of MEMS technology”. In 2011, Dr. Petersen joined the Silicon Valley Band of Angels. Today, he spends most of his time helping and mentoring early stage, high-tech start-up companies.

TITLE

Cepheid: from Rags to Riches

ABSTRACT

In 1996, the “idea” of Cepheid was born. In 2016, Cepheid was acquired by Danaher for $4B. This is the story of that journey. Cepheid was a unique marriage of motivated and tenacious individuals, with a shared, common vision for the future of molecular diagnostics. Cepheid was a once-in-a-lifetime journey through the ups and downs of the legendary Silicon Valley high-tech start-up. In this talk, we will visit the unvarnished inside story of a successful bio-tech start-up. How was the team put together? How was the technology established? What were the crucial decisions that led to its near collapse, but ultimate, almost miraculous success? What were the interactions between Cepheid and the established molecular diagnostics giants of the time? What were the hardest aspects in making the company successful? How did Cepheid leverage government money as non-dilutive funding for product development? How did the brash start-up, Cepheid, become THE leader in such a complicated and regulated industry? These and many other questions will be covered in this talk.

Paul Hung, Ph.D.

CEO

COMBiNATi

BIOGRAPHY

Paul received his B.S. degree from National Taiwan University and his Ph.D. in Electrical Engineering & Computer Science from University of California at Berkeley. He co-founded CellASIC Corporation in 2006 based on his PhD works. CellASIC broke even in 2011 and was acquired by Millpore in 2012. He founded COMBiNATi in 2016 to continue driving his vision of overtaking conventional life science consumables with microfluidic technology. He has 8 issued patents in microfluidics, has secured over $5M SBIR (Small Business Innovative Research) grants from National Institute of Health, and took the CellASIC ONIX live cell imaging platform from lab to marketplace.

COMBiNATi company description: COMBiNATi is a deep microfluidic technology company developing innovative life science platforms. Our initial focus is a one-click cost-effective digital PCR platform for rare genomic biomarker profiling, with synthesized tissue array reactor (STAR) for predictive liver toxicity screening and digital high resolution melt analysis platform for precision early sepsis diagnosis in the pipeline.

Ben Hwang

CEO

Profusa

BIOGRAPHY

Ben Hwang currently serves as the Chairman and Chief Executive Officer of Profusa, a company that has created a wear-and-forget way to stream biochemical data from inside the body to a smart device outside the body, truly transforming the way we measure health and wellness. From his early exposure as an undergraduate research fellow at the lab of Leroy Hood at Caltech, where the automated DNA sequencer was developed, to bringing cutting edge life sciences tools to the market at Life Technologies Corporation (acquired by Thermo Fisher Scientific, Inc.), Ben has seen first-hand the transformative impact that science and technology have to change our world. Prior to Profusa, Ben served in a variety of leadership roles at Life Technologies Corporation, including as President of the Asia Pacific Region and Head of the qPCR Division. A former management consultant at McKinsey and Company, Ben earned his M.A. and Ph.D. in Biology from the Johns Hopkins University. 

Dan Laser

CEO

Applaud Medical, Inc.

BIOGRAPHY

Dan Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, apioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has acted as a board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Applaud Medical is a San Francisco-based start-up developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India.

Ben Wang, PhD

CEO

Chimera Bioengineering

Photo

2.8” (H) X 2.5” (W)

BIOGRAPHY

Dr. Ben Wang is CEO of Chimera Bioengineering, a next generation immunotherapy company he co-founded with Gus Zeiner and Professor Christina Smolke. Prior to his role at Chimera, he was an entrepreneur in residence at StartX, the Stanford affiliated accelerator, where he launched Chimera and advised several hardware and medtech companies. Previously, Ben was a co-founder of Svaya Nanotechnologies, anadvanced materials company commercializing industrial scale layer by layer self assembly for thin film products and was an early contributor at Caliper Life Sciences, pioneering microfluidics for drug discovery. Ben is an advisor to several materials and biotech companies and is passionate about building aligned, motivated and collaborative teams. Ben received his BS in Chemical Engineering from Stanford University and his PhD in Chemical Engineering from MIT.

Chimera Bioengineering: Chimera Bioengineering is a biotherapeutics company building RNA based gene regulatory systems for chimeric antigen receptor (CAR-T) cell therapeutics with greater efficacy against solid tumors and superior safety. Cofounded by renowned synthetic biologist, Professor Christina Smolke, of Stanford University, Chimera leverages the combination of synthetic biology and immunotherapy, to widen therapeutic windows, expand treatment to cancers with unmet needs and create therapies that restore and maintain patient dignity. Chimera'sdifferentiated RNA based technologies enable conditional, realtime control over CAR-T, solving the critical challenges of safety and potency, while extending persistence and efficacy. Chimera is a resident at JnJ's prestigious JLABS incubator in South San Francisco and has the support of StartX, the Stanford affiliated accelerator and Illumina Accelerator.

Chandler D. Robinson, MD MBA MSc

CEO

Monopar Therapeutics Inc.

BIOGRAPHY

Dr. Robinson is Co-Founder and CEO of Monopar Therapeutics. In 2010, Dr. Robinson co-founded and was CEO of Tactic Pharmaceuticals. He helped lead Tactic through a successful sale of its lead compound. His passion is leveraging his interests in medicine, science, and finance to help bring new therapeutics to patients. The compound Dr. Robinson researched at Northwestern University as an undergraduate, and published on in Science, is currently in a Phase III clinical trial for Wilson Disease. Among his previous experiences, Dr. Robinson worked at Onyx Pharmaceuticals in their Nexavar marketing division, as a co-manager of a healthcare clinic in San Jose CA, as Founder and President of an undergraduate research focused non-profit, and at Bear Stearns investment bank. He was previously on the board of Wilson Therapeutics, and is currently on the board of Northwestern University's Chemistry of Life Processes Institute. Dr. Robinson graduated summa cum laude from Northwestern University, earned a master's degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright Scholarship, an MBA from Cambridge University on a Gates Scholarship, and an MD from Stanford University.

Photo 

2.8” (H) X 2.5” (W) 

William Wei VP of America Frontier Science Institute Chief Architect of American Chinese Friendship Council Permanent Reserve Talent of IBM (Server and Cloud Computing)

BIOGRAPHY

William Wei is the VP of America Frontier Science Institute and Chief Architect of American Chinese Friendship Council. Graduated from Beihang University in 1995. Focus on financial software development for HSBC and BOC . In 2005 he joined IBM and Microsoft cloud project on IBM Rochester Lab and got the award of Permanent Reserve Talent of IBM (Server and Cloud Computing). In 2013, he moved to Silicon Valley, engaged application development with Robot, Bigdata, Blockchain, AI technology. In 2017 he involved in life science of emerging frontiers & multidisciplinary activities.

TITLE

Build Scientist Town to Save Lives with Frontier Science and Technology

ABSTRACT

We are building scientist towns to leverage top 1000 scientists working together all over the world. We would initiate projects to save lives and last longer with emerging frontier technology. The topics involve heart disease, cancel, environment protection, food safety, mental depression etc. The technology includes soft micro robot, gene pharmacy, machine learning, AI and so on. At the same time, we are raising funds to help scientists, entrepreneurs and financiers to startup the companies and convert the emerging frontier technology to products. Our target is help human being could live for 500 years old after 10 or 20 years later. Warmly welcome to join scientist towns.

A. Patricia Campbell, Ph.D.,Esq.

Intellectual Property Partner

Jones Day

BIOGRAPHY

Patricia Campbell has more than 10 years of experience counseling clients in all aspects of patent portfolio development in the pharmaceutical and biotechnology sectors. This includes for small molecule pharmaceuticals, antibodies and antibody-drug conjugates, diagnostics, enzyme replacements, and in silico screening methods for drug identification and development, among others. She has prosecuted some of the most valuable patent portfolios covering approved products from several of the world's premier biotechnology/pharmaceutical companies.

In addition to patent procurement and portfolio management, Patricia advises clients regarding patentability, validity, infringement, and freedom-to-operate issues, and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition. She also has experience with inter partes review proceedings and oppositions before the European Patent Office.

Prior to practicing law, Patricia was a tenured associate professor in the Department of Medicinal Chemistry at the University of Washington, where she served as principal investigator on research projects funded by the National Institutes of Health and the Department of Defense.

TITLE

Opportunities for Biosimilar Companies under the U.S. Legal System

Abstract

Congress enacted the Biologics Price Competition and Innovation Act (“BPCIA”) as a provision of the Patient Protection and Affordable Care Act in 2010. The BPCIA establishes an abbreviated route to licensure by U.S. Food and Drug Administration (“FDA”) for biologics shown to possess the requisite level of similarity to an existing FDA-licensed reference product. The BPCIA is intended to increase access to lower-cost biologics, much like what the Hatch-Waxman Act created for generic small molecule drugs. On March 6, 2015, FDA licensed the first biosimilar therapeutic, Sandoz’s Zarxio®, the biosimilar version of Amgen’s anti-cancer biologic Neupogen®. This presentation introduces U.S. biosimilar laws and discusses the opportunities presented to biosimilar companies under U.S. legal system.

Bing Liang 

Bing Liang, Ph.D., Esq.

Associate

Jones Day

BIOGRAPHY

Dr. Bing Liang represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property. Her practice encompasses global patent portfolio development, management, and enforcement, particularly in the areas of biologics and diagnostics.

She prepares and prosecutes patent applications for a broad range of life science technologies, involving antibodies, human embryonic stem cells, therapeutics and diagnostics for cancers, central nervous system diseases, autoimmune diseases, orphan diseases, and whole genome sequencing.

Bing advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals. She is experienced in licensing agreements and matters related to FDA approval.

Her practice also includes various post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), including inter partes reviews (IPRs).

Ho Family Scholarship

The Ho Family Scholarship is established in memory of Ellen & Tony C. Ho. It is also intended to continue the family’s tradition of supporting educational endeavors. The family had founded the Chi Yong School in Guangzhou, China and Saigon, Vietnam in the past.

Ellen Ho, a nurse practitioner, worked at Tung Wah Hospital in Hong Kong for over thirty years. She held the position of Head Nurse in the maternity ward before retiring. Tony C. Ho, a chemist by training, worked at Taiwan Sugar in Ping Dong and at San Miguel Brewery in Hong Kong. He joined Merck Sharp & Dohme in 1960, and worked as Plant Manager in Bangkok, Thailand, for over 20 years, followed by 10 years at Merck & Co. Headquarters in Rahway, New Jersey.

There will be two Ho Family Scholarships each consist of an award of $500 in 2017.

Caesar Ho, the eldest son of Mr. and Mrs. Ho, will serve as the sponsor on the CBA Board. Yvonne Ho & Erika Ho, grand daughters of Mr. and Mrs Ho, will serve as alternate sponsors.

The selected candidates for the Ho Family Scholarships will be announced at the 20th CBA Annual Conference.

Philippe Bishop, MD

Founder, EVP, CMO

aratinga.bio, Inc.

BIOGRAPHY

Dr. Bishop is a physician-scientist and biotech executive with more than 20 years of drug development experience. In 2017, he co-founded aratinga.bio, a preclinical stage company developing first-in-class immunotherapies to treat cancer. Prior to aratinga.bio, he held executive leadership roles at Gilead, Genentech, Johnson& Johnson, and served in roles at the U.S. Food and Drug Administration and the National Institutes of Health (NIH). During his seven-year tenure at Genentech/Roche, Dr. Bishop served as vice president of clinical development, angiogenesis franchise head, overseeing the clinical development of Avastin. At its peak, the program included more than 450 clinical trials, which resulted in 11 approved indications that drove revenues of ~$8B annually. Dr. Bishop earned his medical degree from the University of Nevada School of Medicine, and was a Howard Hughes Medical Institute/NIH research scholar. He completed training in internal medicine at University of Washington School of Medicine, and went on to a medical oncology fellowship at the National Cancer Institute.

TITLE

Avastin’s Development: The Case Study for Mega Brands

ABSTRACT

Avastin® (bevacizumab; Genentech, Inc., South San Francisco, CA, USA) is a humanized monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF-A). It is the first anti-angiogenic medicine approved by the FDA in February of 2004, and today is approved to treat 7 types of cancer, including colon, lung, breast, ovarian, cervical and certain kinds of brain and kidney cancer. A unique flexible business model enabled collaboration with academia, industry, and regulators to form, which resulted in a development program with more than 450 studies across more than 30 tumor types. The Avastin development program was the first to demonstrate the importance of the tumor microenvironment in the therapeutic management of cancer highlighted by 14 original New England Journal of Medicine articles and 10 American Society of Clinical Oncology Plenary Presentations. Pushing many boundaries, the program was at the center of many controversies but ultimately helped redefine industry/academic collaboration, clinical trial design and regulatory pathways for approval. Today, Avastin development represents the culmination of many years of biologic and human research around the world and serves as a roadmap for other blockbusters programs in development today.

James Mu, Ph.D.

Director; Discovery Team Lead

MRL San Francisco

BIOGRAPHY

Received Ph.D. from Indiana University School of Medicine.Major training in signal transduction and carbohydratemetabolism

HHMI Postdoctoral fellowship at University of Pennsylvania.Major areas of interest include role of AMPK and Aktpathways in metabolic regulation

Joined Merck Research Laboratories Diabetes & Obesitygroup (New Jersey) in 2004 as a Senior Research Biologist

Has worked on a broad range of projects (e.g. Januvia,GRA, FGF21 and novel insulins) covering new targetvalidation, lead identification / optimization, clinicalcandidate development and commercial product life-cyclemanagement

Led modality agnostic drug development projects in closecollaboration with academic, CRO and biotech laboratories

Relocated to Bay Area in 2017 in support of MRL SanFrancisco Site development

TITLE

Merck San Francisco: Commitment to Science-driven Transformational Medicines

ABSTRACT

Merck is building its west coast research center, Merck Research Laboratories South San Francisco. The new multi-disciplinary discovery research site offers state-of- the-art resources to explore the most promising science combined with Merck’s world-class R&D expertise in small molecules and biologics. Located within the heart of the Bay Area’s biomedical community, research conducted in our new laboratories spans exploratory biology through early clinical development and is an integral part of Merck’s powerful network of drug and vaccine discovery. I would like to highlight our mission for the new site and share an example of our recent experience in developing innovative insulins. Current insulin therapies are limited by their low intrinsic therapeutic index. As a result most patients are consistently undertreated (to avoid hypoglycemia) and fail to achieve treatment targets, leading to high prevalence of diabetic complications. A “smart” insulin that only works at high ambient glucose concentrations has long been considered a “holy grail” of insulin therapy. Merck initiated the potentially transformational glucose-responsive insulin effort with the goal of improving efficacy and reducing hypoglycemic risk simultaneously.

Ji Li, PhD

Executive VP and Global Head of BD

BeiGene

BIOGRAPHY

Dr. Ji Li has more than 20 years of business development and R&D experience in the biopharma industry. He is currently Executive VP and Global Head of BD at BeiGene where he oversees the company’s partnering activities worldwide. Prior to BeiGene, Dr. Li served as VP of BD&L at Merck, where he was responsible for BD activities of all late-stage inbound and outbound opportunities globally. Prior to Merck, Dr. Li was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Earlier in his career, Dr. Li was key member of the Amgen research team discovered and validated the RANKL signaling pathway that has led to the successful development of Denosumab. Dr. Li obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York.

TITLE

Transformation of BeiGene via Business Development and Partnership

ABSTRACT

BeiGene was founded in 2011 as an oncology discovery startup based in Beijing, China. Today, BeiGene is listed on the NASDAQ market as a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 700 employees in China, the United States, and Australia, BeiGene is advancing an internally discovered pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In addition, BeiGene markets ABRAXANE®, REVLIMID®, and VIDAZA® in China under a license from Celgene Corporation. I will discuss the essential role business development and partnership played in transforming BeiGene from a discovery oncology startup into a fully integrated biopharmaceutical company with discovery research, clinical development, small molecule and biologic manufacturing and commercialization capabilities in such short period of time.

Jing-Shan “Jennifer” Hu, Ph.D

Partner

Qiming US Healthcare Fund

BIOGRAPHY

Dr. Jing-Shan “Jennifer” Hu is Partner of the US Healthcare Fund of Qiming Venture Partners. Before Qiming, she was VP and Head of (External) Innovation Center China at Bayer Healthcare, responsible for building and managing partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director of Licensing & External Research at Merck&Co covering Greater China for Worldwide Licensing & External Research. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ. She is a board member of BayHelix and Chinese-American BioPharma Society (CABS).

Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received an MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.

Alexis Ji, Ph.D., MBA

Partner

Illumina Ventures

BIOGRAPHY

Alexis Ji is a partner at Illumina Ventures. Alexis brings 13 years of experience in research and venture investment in the genomics and pharmaceutical industries. Founded in 2016, Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. Illumina Ventures focuses on investing in early-stage companies in the fields of life science tools, therapeutics, diagnostics, and personal wellness, with the aim to help entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare.

Prior to Illumina Ventures, Alexis was a principal at WuXi Healthcare Ventures, a U.S.-China cross-border life science venture capital firm, where she focused on investments in therapeutics and medtech companies in the U.S. Some of the investments Alexis was heavily involved in included Twist Bioscience, 23andme, Juno Therapeutics, Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, and Ideaya Therapeutics. Before joining WuXi, Alexis was a venture investment consultant at ARCH Venture Partners, where she evaluated early-stage life science and physical science opportunities and was involved in the founding of Twist Bioscience and the investment in Nextcode Health.

Earlier in her career, Alexis held senior scientist positions at Merck in early drug discovery, at Roche in virology translational research and clinical trial development, and at Life Technologies in molecular diagnostics and next-generation sequencing.

Alexis earned her Ph.D. in Molecular Genetics from Washington University in St. Louis and an MBA from University of Chicago Booth School of Business.

Rajeev Dadoo, PhD 

Partner 

SR One 

BIOGRAPHY

Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program. His current investments include True North, Propeller Health, Tranquis, Illuminoss and Avhana and was he previously involved with iPierian, Cydex, Hypnion and Neuro Therapeutics Pharma. In addition to his role at SR One, Rajeev spent time with the Competitive Excellence group within GSK working on company-wide strategic projects for GSK’s Corporate Executive Team. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked at Genome Therapeutics in the business development role. Rajeev was a co-founder of Unimicro Technologies, a company that was created to develop and commercialize instrumentation for biomedical analysis. Rajeev received his BA degree in Chemistry and Mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania, and his PhD in Chemistry from Stanford University.

Vincent Xiang, PhD 

Partner 

Six Dimensions Capital 

BIOGRAPHY

Dr. Vincent Xiang is a Partner of 6 Dimensions Capital. He has over 20 years of experience in the life sciences industries in the U.S. and China. From 2013 to 2016, Dr. Xiang was Managing Director and Head of international investments & business development at Humanwell Healthcare Group (600079.SH), which has $1.3B/year in revenue in 2015. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, scouting first in class assets. From 2004 to 2012, Dr. Xiang was Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages. Previously, he was Vice President of business development at Genyous, a US biotech start-up. He was also Director of venture investment at Acacia Research, Associate at BioAdvance (a healthcare Angel fund), and Irvington Fellow at Skirball Center and licensed his patented technology to Millennium Pharmaceutical for royalty payments. Dr. Xiang began his career at Sinopharm in China. Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups. 

Lee-Cheng (L-C) Liu, Dr.Eng.Sci.

President & CEO

EirGenix, Inc.

BIOGRAPHY

Dr. Liu has more than 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty chemical industries. Prior to returning Taiwan to start up EirGenix, Dr. Liu was the President and COO of AnGes Inc., a late developmental stage biotech enterprise. He joined AnGes in 2002 as a Vice President of Product Management. He also served as a Vice Chairman in the Supervisory Board of Avontec GmbH, a Munich based joint venture with AnGes, from 2004 to 2010. Before his tenure with AnGes, he served various management and professional positions to lead product/process development at GenVec, Novartis, W.R.Grace & Co. and Halcon SD. Dr Liu holds a doctoral degree in Chemical Engineering & Applied Chemistry from Columbia University, and a BS degree in Chemical Engineering from National Taiwan University.

TITLE

From the development history of EirGenix to examine the recent changes of the biotech sector in Taiwan financial market

ABSTRACT

EirGenix was established at the end of 2012 as a business entity to complete the acquisition of cGMP Biopharmaceutical Pilot Facility, which was owned by Development Center for Biotechnology and decided to spin off the unit to improve its operational efficiency. A short five years development history for EirGenix, it has been remarkably growing its CDMO business for more than 30 fold, in the mean time, it has also established a solid and unique product pipeline. It went through a prosperous period of Taiwan financial market for biotech sector during this growth period of the Company. Why does the biotech sector turn out to be a such “frozen winter” recently while the TAIWAN Index reached over 10,000 point in the historical longest period of time? The speaker would like to share his own views of the recent changes with the audience .

Ray (Rui) Chen Ph.D.

Sr. Director of Sales & BD

GenScript

BIOGRAPHY

Dr. Ray (Rui) Chen is Sr. Director of Sales and Business Development of GenScript, a leading biology CRO in the world. Dr. Chen is responsible for North America businesses, strategy planning and implementation for all service lines at GenScript including gene synthesis, peptide, protein and antibody productions, and genome editing. Dr. Chen served at Procter & Gamble before joining GenScript, responsible for laundry product designs and launches at emerging markets. Dr. Chen is the author of multiple peer reviewed publications, including Nature and JACS, and book chapters. Dr. Chen studied peptide chemistry in Dr. Richard DiMarchi lab and earned his PhD in Chemistry from Indiana University Bloomington and BS in Chemistry from Nanjing University.

ABSTRACT

GenScript (publicly traded in Hong Kong Exchange, 1548.HK) is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a global leading biotech company that provides life sciences services and products to scientists over 100 countries worldwide. As of 2016, more than 13,000 peer-reviewed journal articles cited GenScript’s services and products, making GenScript the most frequently cited Biotech Company in the world. During our tenure we have built the best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.

Amit Chaudhuri

VP R&D

MedGenome Inc.

BIOGRAPHY

Dr. Amit Chaudhuri has extensive industrial experience in oncology target discovery and validation from Genentech Inc. and CuraGen Corporation prior to his role as VP, R&D at MedGenome. He has Ph.D. in Biochemistry from Indian Institute of Sciences, Bangalore and did his Postdoctoral research at MGH, Harvard Medical School and at the Department of Molecular and Cellular Biology, Harvard University.

TITLE

The power of population isolates for discovery research

ABSTRACT

Most common human diseases have an underlying genetic basis and runs in families and/or in specific ethnic groups. Conventional linkage analysis of affected families and/or disease cohorts have led to the discovery of causal genes of large effect size in diabetes, cholesterol metabolism, familial breast and colorectal cancer, among others. However, linkage analysis cannot be applied to identify disease-causing variants in complex diseases, since the disease traits are polygenic, contribution of individual genes to the overall disease phenotype is incremental, and their effects are modulated to a large extent by environmental factors. These findings suggest that there are many, yet undiscovered, genes and genetic loci that contribute to the development of the disease phenotype. This is the ‘dark matter’ of missing heritability. Unlocking these missing pieces of heritability require 1. Genetically diverse population that have originated from a small founder population; 2. Large disease cohorts; and 3. Life style and environmental factors that may affect the disease phenotype. In this presentation, we argue that the Indian population represents a unique blend of naturally stratified, yet genetically diverse group of individuals that can be leveraged to investigate complex diseases and disease phenotypes. Identifying and analyzing these subpopulations can lead to the discovery of disease alleles that have modest to low effect size on disease risk.

Dan Zhang, PhD

Chairman and CEO

Fountain Medical Development Ltd,

BIOGRAPHY

Dr. Dan Zhang is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with 1200 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia and USA.

Dr. Zhang was the Head of Clinical Development at Sigma-Tau Research Inc, He was a vice president at the Quintiles Transnational Corp. and the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd.,

Dr. Zhang is a member of grant application review committee for National Key Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and is the secretary-general of the Association of “Thousand Talent” Expert

Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received an MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.

A Letter from the Chinese Biopharmaceutical Association (CBA) President

Dr. Dong Shen is head of computational and biomarker in lung and prostate disease area strongholds at Janssen Pharmaceutical companies of Johnson and Johnson. Previously, Dr. Shen worked as a senior bioinformatics and computational biologist at AstraZeneca in Gaithersburg and Washington University genome institute in Saint Louis. Dr. Shen graduated with Ph.D. degree from Johns Hopkins University School of Medicine and M.D. degree from Shanghai Jiao Tong University School of Medicine. Dr. Shen lead TCGA breast cancer, lung cancer, ovary cancer and AML projects. All his manuscripts been published at top peer reviewed journals, such as New England Journal of medicine, Nature, Science, Cell, JAMA, Nature genetics, etc. The total number of his citations is over 11,000. Currently Dr. Dong Shen is the President of Chinese Biopharmaceutical association (CBA) and the Chair of CBA board of directors.

Dear CBA-SF Members and Friends:

As the President of Chinese Biopharmaceutical association (CBA) and Chair of CBA board of directors, I am greatly honored to be invited and attend CBA-SF Annual Conference. Here I would give you a brief introduction of CBA. The Chinese Biopharmaceutical Association-USA (CBA) (www.cba-usa.org) is one of the largest Chinese American professional associations in the US. Founded in 1995 by a group of Chinese-American biopharmaceutical professionals, CBA is an independent, non-political, and non-profit professional organization headquartered in the Washington DC area. The membership now comprises more than 6,000 biopharma-related professionals from industry, academia, and government. Over 80 percent of the members hold Ph.D., M.D. and/or J.D. degrees. CBA also has over one hundred Institutional Members. The mission of CBA is to promote communication and collaboration among biopharmaceutical professionals and to promote technology transfer and business collaborations among different countries and regions, especially between the United States and China. It has been two tumultuous decades of growth for the CBA. Twenty-two years ago, we were a tiny group of young scientists. But we had a big vision: to create a platform for collaboration in life sciences and the biopharmaceutical industry. Thanks to the dedication of our members, CBA has grown into a truly global organization with a strong and growing reputation. We have remained true to our founding mission, and this conference will serve to reinforce and extend the commitment of CBA to fostering greater global collaboration and new partnerships between China and USA in the biotech and pharmaceutical arenas.

Sincerely, Dong Shen

================= Dong Shen, M.D., Ph.D. President, CBA-USA Chair, Board of CBA Cell: 410-258-5555 Email: shendong@gmail.com

MISSION

The Chinese Bioscience Association (CBA) is a non-profit organization founded in the San Francisco Bay area in 1997. Its mission is to promote education, networking and community building for Life Sciences professionals.

LOCAL PARTICIPATIONS

CBA has held hundreds of scientific conferences, seminars and workshops focusing on emerging trends and cutting-edge technologies in the biotech/pharmaceutical industry. CBA currently has hundreds of active members and supports, ranging from company founders, CEOs, business executives, directors, managers, scientists, academic professors, researchers, postdoctoral fellows and students.

GLOBAL CONNECTIONS

As a bi-lingual organization, with strong ties to China, Taiwan, Hong Kong and Singapore, CBA plays a vital role in bridging the industry and cultural gaps between US and Asia. All events, especially the Annual Conferences and educational workshops, are popular with members, and friends. CBA is a volunteer-based organization generously supported by its members and sponsors.

Q4 2016 to 2017 EVENTS AND ACTIVITIES

Oct. 8, 2016 Oct. 8, 2016 Apr. 12, 2017

Apr. 29, 2017 Jul 9, 2017 Aug. 19, 2017 Sep. 18 2017

19th CBA Annual Conference 2016 Ho Family Scholarship Award Meeting with CEO and Business Development Manager of 億觀生技

(Aidmics Biotechnology) CAN Program (Career Advisory Network) Meeting with Sichuan Government Delegation 2017 CBA Annual Summer Picnic at Mitchell Park, Palo Alto Aug. 19, ITRI and DCB event

2017 BOARD and ADVISORS

President: Patrick YangVice Presidents: Mark Chen and Huifang LiSecretary: Thomas WeiTreasurer: Katherine WangMembership: Vivian FuPublic Relations: Thomas Weie-Communication: Pengguang WuPublications: Fu-Ning Hsu and Lena FengSponsorships: Lena Feng and Susan LiangAlliances: Wenyi ChenScholarship: Caesar HoNewsletter / CABS mentoring collaboration: Mark Mengjianhong AureliusLogistics: Ta-Kai LiConference Advisors: Ravi Mistry and Cheni Kwok,Volunteers: Laurie Wu, Lindsey Xie, Jane Wu and Keith CheungAdvisors: Patty Kiang, Lin Sun-Hoffman, Michelle Chen, Kai Zheng, Kelley Liu, Shian-Jiun (SJ) Shih, Shih-Chen Chang and Sydney ChenSpecial Thanks to: Julie Yang, Yang Pan, Frank Meng, Li-Ming Liang, Carla Liang-ChinChen and Debbie Jen

1998 - 2016 OfficersYear President Vice President Secretary Treasurer2016 Kai Zheng Mark Chen Yuan Zhang Katherine Wang2015 Shih-Chen Chang Cheni Kwok/Kai Zheng Mark Chen Katherine Wang2014 Michelle Chen Patty Kiang Mark Chen Katherine Wang2013 Lin Sun-Hoffman Shih-Chen Chang Angie Wu Katherine Wang2012 Peiwen Yu Son Kuan/Andrew Teng Shwu-Hwa Lin Katherine Wang2011 Patty Kiang Li-Fen Lee Cindy Liu Katherine Wang2010 Sydney Chen Patty Kiang/Yong-Liang Zhu Ta-Kai Li Katherine Wang2009 Stella Chang Sydney Chen Ta-Kai Li Wei Chen2008 Lichun Huang Cheng-Chi Chao Stella Chang Wei Chen2007 Kelley Liu/Fong-Yih Bih Cheng-Chi Chao Stella Chang Wei Chen2006 Betty Chang Fong-Yih Bih N/A N/A2005 Joshua Chang Betty Chang N/A N/A2004 Jer-Kang Chen Joshua Chang N/A N/A2003 Effie Lin Jer-Kang Chen N/A N/A2002 Jin-Chen Yu Effie Lin N/A N/A2001 Maureen Wang/Jin-Chen Yu Effie Lin N/A N/A2000 Maureen Wang Jin-Chen Yu N/A N/A1999 James Fann Maureen Wang N/A N/A1998 Shian Jiun Shih James Fann N/A N/A

CBA 19th Annual Conference 2016 and 2016 Ho Family Scholarship

Date/Time: October 8, 2016 8:30 am – 4:30 pm

Venue: Crowne Plaza, Foster City, CA

The scholarship winners last year were Claire Zhang of Monta Vista High School and Veronica Zhao of Lynbrook High School.

Meeting with CEO and Business Development Manager of 億觀生技

(Aidmics Biotechnology)

Date/Time: April 12, 2017

Venue: Milpitas

億觀生技 (Aidmics Biotechnology) is a Taiwan-based company that developed aninnovation product called iSperm. On April 12, CBA board members hosted a lunch withthe visitors in Milpitas. We hope this meeting is the beginning of a wonderful relationshipbetween our organization and the industry in Taiwan.

Agean Lin, CEO (Left 4 ) Jolanda Hsu, Business Development Manager (Right 3)

CAN Program (Career Advisory Network)

Date/Time: April 29, 2017

Venue: Hanqi Investment, Burlingame

The CAN Program Kickoff Meeting was held at Hanqi Investment, Burlingame on April 29, 2017. CBA members joined this program as both mentors or mentees. This program is run in collaboration with the Chinese American Biopharmaceutical Society (CABS). It is a mentoring program designed to help advance career goals in the life science industry through mentoring, skills building, and networking. It offers a six-month program with 1:1 mentoring meeting, brunch gathering, and group network sessions.

CAB mentors: Kai Zheng, Wenyi Chen, Caesar Ho, Patty Kiang, Ta-Kai Li, Vivian Fu, Yen-Chi Wu, Lin Sun-Hoffman, Pengquang Wu, Shian-Jiun Shih and Michelle Chen.

Meeting with Sichuan Government Delegation

Date/Time: July 9, 2017

Venue: Fairmont Hotel San Francisco

On July 9, at Fairmont Hotel San Francisco, Sichuan government delegation led by governor, Yin Li, met twenty Bay Area/Silicon Valley Chinese high tech and bio tech professionals. These professionals are from different associations and universities. CBA' current president, Patrick Yang, and former president, Lin Sun-Hoffman, attended the meeting.

CBA Summer Picnic

Date/Time: August 19, 2017, 11:00 am – 2:00 pm Venue: Mitchell Park, 600 East Meadow Drive, Palo Alto, CA

A fun weekend for the families of CBA members and friends with an attendance of over 80. Good music and great food. Excellent time to catch up with old friends and networkwith new friends.

ITRI and DCB event

Time: 12:00 to 2:30 pm, Sept. 18, 2017 Venue: Joy Restaurant, 1489 Beach Park Blvd, Foster City, CA 94404 Event Coordinator: Sean S.H. Wang, President of ITRI International Inc. (a subsidiary of ITRI)

In this exceptional luncheon host by ITRI and DCB, Dr. Chii-Wann Lin, the Vice President & General Director of Biomedical Technology and Device Research Laboratories from ITRI, and Herb Wu, Interim CEO of Development Center for Biotechnology (DCB), came to invite networking between them and biotech and pharmaceutical companies at Bay area for collaborative opportunities in US, Taiwan, as well as nations all over the world.

It was a great and successful event with multiple presentations, including led by Dr. Lin and Dr. Wu, and after following by guests from different companies to exchange their past experiences and also to discuss their future directions in biomedical field.

CBA would be delightful to continue on promoting communications in biotech and industry communities at Bay Area through support of nation-wide interactivities with our commitment.

1998 President Shian-Jiun (SJ) Shih It felt like yesterday when a group of life scientists started gathering for learning from each other 23 years ago. After this gathering became a part of our life, we registered a non-profit organization under the name Chinese Bioscience Association 20 years ago. It is with great honor and happiness to say: Happy 20th Birthday, CBA. Congratulations and salute to everyone who makes this anniversary possible and keeps CBA going strong to continue serving its members.

1999 president James Fann I remembered 23 years ago we just started our career and looked for connections, so we got together to establish CBA. It is so nice to see the CBA still exists and prosperous today

2002 President Jin-Chen Yu Take care and enjoy your CBA network. It can blossom at times you never know.

2003 President Effie LinIt is amazing how CBA has grown from a few bioscience post-doctoral community to a well-recognized professional organization in Bay Area. Congratulations!

2005 President Joshua Chang Congratulations on CBA's 20th anniversary! Let's reconnect when you have a chance to visit Taiwan

2006 President Betty Chang CBA has always been of the scientists, by the scientists, and for the scientists. I am proud to be a CBA member, and happy 20th anniversary! Long live CBA.

2007 President Fong Yih Bih

2007 President Kelley Liu I joined the board ten years ago and have witnessed the tremendous growth with increased representation from key biotech sectors and public visibility by bringing about greater community participation and support. The long-term commitment of so many wonderful people in this organization is impressive. I am very proud that we have built an enduring organization that will weather a world of changes in the era of biosciences revolution. 轉眼二十載 深耕生技 柳成蔭

2008 President Lichun Huang It is such a privilege to be part of the history and a member of the community. Let’s network!

2009 President Stella Chang The CBA has every reason to celebrate its 20 h anniversary. It is an exceptional organization and deserves to be proud of their achievements. It fulfills its mission in every way, and does more. Many scientist and bioscience students were benefited from the seminars and conference meetings. To all who have contributed and all who contribute as CBA moves forward, we say thank you!

2010 President Sydney Chen It has been my utmost privilege to participate from the beginning of CBA and over the years see CBA grew from a small group of enthusiastic volunteers into one of the major professional organizations in SF Bay Area, with hundreds of active members working in all aspects of bioscience industry. With the 20th birthday of CBA coming up, a sincere wish to CBA towards another great twenty years ahead.

2011 President Patty H. Kiang It was my pleasure serving as president of CBA in 2011. CBA is a good organization for networking with Bio/Pharm colleagues in SF area and around the world. Really enjoy to be a life member of CBA. Congratulations on the 20th anniversary of CBA!

2012 President Peiwen Yu With a brilliant team of dedicated members and with your commitment and sincerity, you have proved your worth and have gained the much deserved recognition and success. Working with you has been a real honor and best wish you all the success for many more years to come.

2013 President Lin Sun-Hoffman Wish CBA continue to be prosperous in next 20 years!

2014 President Michelle Chen CBA plays a key role in bridging the gaps of bioscience industry and cultures between US and Asia. I joined CBA in 2009 and was fortunate to serve as its President in 2014. I am so proud of what it has accomplished and look forward to seeing its continuous growth in the future.

2015 President Shih-Chen Chang Congratulations to CBA for achieving the 20 years milestones to serve the life science professionals community in the Bay Area!

2016 President Kai Zheng CBA has been an important bridge to connect Asia Pacific and United State. Wish CBA continued success and become more influential in the bioscience area.

Diamond Sponsors:

Platinum Sponsors:

Jade Sponsors:

Gold Sponsors:

Silver Sponsors:

Non-profit Organizations:

Facility Sponsor:

Private Sponsors: Dr. Jo ShenDr. Dean Tsao

Bay Area TaiwaneseBiotechnologyAssociation (BATBA)

. Cell Line Model Generation

. Mouse/Rat Model Generation

. iPSC Generation & Di�erentiation

Phone 408.773.8007 Email info@appliedstemcell.comwww.appliedstemcell.com

New Lentivirus CRISPR Knockout Service

Neurotoxicity Testing/Phenotype AnalysisFFPE service

Reference StandardsIsogenic Cell Lines

我们支持并赞助湾区华人生物科技协会

OUR NEW FACILITY WILL SCALE OUT YOUR SUCCESS

EIRGENIX, THE LEADING CDMO IN TAIWANEirGenix, Inc. is a new Asia Development & Manufacturing Hub for Biologics that offers high quality and cost-effective services to support clients from around the world. The � rm currently owns and operates two cGMP compliant plants, producing microbial expression system and mammalian expression system based biologics. We can provide services all the way from cell line development to releasing of drug substance.

OUR NEW FACILITYA new commercial facility located in Zhubei Medical Science Park is currently under construction and will be initially ready for service in 2018. 12 x 2000L Single Use Bioreactor (SUB) system for mammalian cell culture will be on line to scale out your commercial success. In addition, there will be a 1000 Liter Stainless Steel fermentation system and two downstream puri� cation suites for microbial expressed protein production.

OUR CAPACITYScale out from 2000 Liter to maximum 12 x 2000 Liter

12 x 2000 Liter

SINGLE USE BIOREACTOR

Maximum 1000 KG

ANNUAL mAbs PRODUCTION CAPACITY

CLIENT’S SUCCESS IS OUR PRIORITY

ADDRESSNo. 101, Lane 169, Kang Ning Street, Xizhi

District, New Taipei City 22180, Taiwan R.O.C.

CONTACT USservice@eirgenix.com

+886-2-7708-0123

WEBSITE

www.eirgenix.com

CLIENT’S SUCCESS IS OUR PRIORITY

WEBSITE

www.eirgenix.com

EirGenix

ITRI isoneoftheworld’sleading technologyR&Dinstitutionsaiming toinnovateabetterfutureforsociety. Based onits long-termpartnershipwithvariousindustrysectors, ITRI offersawiderangeofservices, fromtechnical tobusinessconsultation, totheinternational community– suchascontractresearch,productandprocessdevelopment, andpilotrunsfortechnological upgrades; IPstrategyandlicensing, industrialanalysis,andtalenttrainingforhi-tech business;andtheopenlabandincubationfornewventuresandemergingindustries. TheInstitute hasalsoincubatedmorethan240innovativecompanies since 1973,includingwell-knownnames suchasUMCandTSMC.Headquartered inTaiwan, ITRIhasfivebranchofficesinSiliconValley (ITRIInternational Inc.),Tokyo,Berlin,Moscow,andEindhoventoextenditsR&Dinnovationacrosstheglobe.

Taiwan Hsinchu‧San Jose‧Tokyo‧Berlin‧Moscow‧EindhovenITRI Headquarters, Hsinchu, Taiwan, R. O. C.; +886-3-582-0100 ITRI International Inc., San Jose, CA, USA; information@itri.com

SmartLivingSmartEndpointsMechanical SystemsTechnologiesCloudService andBigDataTechnologyInfrastructureandService Platform

QualityHealthMedical DevicesBiomedical TechnologiesTechnologies forHealthcare

SustainableEnvironmentEnergyTechnologiesEnvironmentTechnologiesEnergyConservationTechnologies

http://www.itri.org.tw

selective operations in support of entrepreneurs

Match international startups with prototype partners in Taiwan for design/marketing services and

value added product development to quickly and effectively implement creative ideas.

Facilitate industrial cooperation and investment between

prospective partners, including late-stage startups,

from Taiwan and the U.S.

Assist Taiwan startups to engagewith the Silicon Valley

venture ecosystem

© 2017 Tessa Therapeutics. All rights reserved.

We believe that there is a cure for cancer.That’s why we are dedicated to revolutionize cancer treatment at Tessa Therapeutics. We are conducting the world’s largest Phase III trial in solid tumor T cell therapy. We are a fast-growing immunotherapy company breaking new ground in cell therapy. Our Virus-Specific T cell platform technology shows compelling safety, efficacy, and persistence.Our robust pipeline gives us the hope to soon be able to treat a majority of malignancies and offer patients prolonged survival benefits.

Our scientists are changing the world every day. Be a part of the team. Learn more at www.tessatherapeutics.com

Merck is inventing because the world still needs cures for cancer, Alzheimer’s disease, HIV, and so many other causes of widespread suffering.

We believe that building strong partnerships is critical to solving these challenging diseases — to help people go on, unburdened, to experience, create and live their best lives.

Together we can invent for life.

Learn more at merck.com/licensing.

Merck is known as MSD outside the United States and Canada. Copyright ©2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. 8-17

MERCK BUSINESS DEVELOPMENT & LICENSINGINVENT WITH US

 

Advancing Therapeutics, Improving Lives.

For more  than  30  years, Gilead  Sciences  has  been revolutionizing  healthcare  by  bringing  urgently needed medicines to millions of patients in the areas of  HIV/AIDS,  liver  diseases,  hematology  and oncology, inflammation and respiratory diseases. 

 As  a  result  of  Gilead’s  continued  investment  in research and development, we are  looking to  invite those with a genuine commitment to science to play a critical role in transforming and simplifying care for people with these life‐threatening illnesses.

 

 Gilead’s  unique  operational  environment  allows  exceptionally  talented  professionals  gain  rapid  skills  and knowledge growth while supporting Gilead’s patient driven mission.   Connect today to be part of an organization that has helped millions of people around the world live healthier and more fulfilling lives.   

www.gilead.com/careers 

 

© 2009-2017 Gilead. All rights reserved